These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32824296)

  • 1. Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
    Ueda H; Neyama H; Matsushita Y
    Cells; 2020 Aug; 9(8):. PubMed ID: 32824296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid and its receptors LPA1 and LPA3 mediate paclitaxel-induced neuropathic pain in mice.
    Uchida H; Nagai J; Ueda H
    Mol Pain; 2014 Nov; 10():71. PubMed ID: 25411045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidic acid-3 receptor-mediated feed-forward production of lysophosphatidic acid: an initiator of nerve injury-induced neuropathic pain.
    Ma L; Uchida H; Nagai J; Inoue M; Chun J; Aoki J; Ueda H
    Mol Pain; 2009 Nov; 5():64. PubMed ID: 19912636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
    Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LPA
    Wang F; Liu S; Pei J; Cai L; Liu N; Liang T; Dong X; Cong X; Chun J; Chen J; Hu S; Chen X
    Theranostics; 2020; 10(24):10892-10907. PubMed ID: 33042260
    [No Abstract]   [Full Text] [Related]  

  • 6. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY; Oh YS; Choi JW; Jung JY; Jun HS
    Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysophosphatidic acid LPA
    Ueda H; Neyama H; Sasaki K; Miyama C; Iwamoto R
    Neurobiol Pain; 2019; 5():100020. PubMed ID: 31194070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia.
    Ueda H
    Pain Manag; 2020 Jan; 10(1):43-53. PubMed ID: 31852400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LPA receptor1 antagonists as anticancer agents suppress human lung tumours.
    Zhao PF; Wu S; Li Y; Bao G; Pei JY; Wang YW; Ma Q; Sun HJ; Damirin A
    Eur J Pharmacol; 2020 Feb; 868():172886. PubMed ID: 31866407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid receptor
    Hoshino Y; Okuno T; Saigusa D; Kano K; Yamamoto S; Shindou H; Aoki J; Uchida K; Yokomizo T; Ito N
    FASEB J; 2022 Apr; 36(4):e22236. PubMed ID: 35218596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesic effects of novel lysophosphatidic acid receptor 5 antagonist AS2717638 in rodents.
    Murai N; Hiyama H; Kiso T; Sekizawa T; Watabiki T; Oka H; Aoki T
    Neuropharmacology; 2017 Nov; 126():97-107. PubMed ID: 28859883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systems Pathology of Neuropathic Pain and Fibromyalgia.
    Ueda H
    Biol Pharm Bull; 2019; 42(11):1773-1782. PubMed ID: 31685762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice.
    Rancoule C; Attané C; Grès S; Fournel A; Dusaulcy R; Bertrand C; Vinel C; Tréguer K; Prentki M; Valet P; Saulnier-Blache JS
    Diabetologia; 2013 Jun; 56(6):1394-402. PubMed ID: 23508306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidic acid and its receptor LPA
    Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
    Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki-16425, a lysophosphatidic acid 1 receptor antagonist.
    Ma L; Matsumoto M; Xie W; Inoue M; Ueda H
    J Neurochem; 2009 Apr; 109(2):603-10. PubMed ID: 19222705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPA1 receptor activation promotes renal interstitial fibrosis.
    Pradère JP; Klein J; Grès S; Guigné C; Neau E; Valet P; Calise D; Chun J; Bascands JL; Saulnier-Blache JS; Schanstra JP
    J Am Soc Nephrol; 2007 Dec; 18(12):3110-8. PubMed ID: 18003779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic blockade of LPA
    Sánchez-Marín L; Ladrón de Guevara-Miranda D; Mañas-Padilla MC; Alén F; Moreno-Fernández RD; Díaz-Navarro C; Pérez-Del Palacio J; García-Fernández M; Pedraza C; Pavón FJ; Rodríguez de Fonseca F; Santín LJ; Serrano A; Castilla-Ortega E
    Neuropharmacology; 2018 May; 133():189-201. PubMed ID: 29378212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
    Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
    Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts.
    Olianas MC; Dedoni S; Onali P
    Biochem Pharmacol; 2015 Jun; 95(4):311-23. PubMed ID: 25888927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.